Cytosorbents (NASDAQ:CTSO) Share Price Passes Above Two Hundred Day Moving Average - Here's Why

Cytosorbents Co. (NASDAQ:CTSO - Get Free Report)'s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.05 and traded as high as $1.16. Cytosorbents shares last traded at $1.13, with a volume of 109,611 shares changing hands.

Analyst Ratings Changes

CTSO has been the subject of a number of research analyst reports. D. Boral Capital reissued a "buy" rating and set a $10.00 target price on shares of Cytosorbents in a report on Tuesday, February 25th. StockNews.com started coverage on Cytosorbents in a report on Tuesday. They set a "hold" rating for the company. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $4.67.

Cytosorbents Stock Up 2.7 %

The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The business has a 50-day moving average price of $1.06 and a 200-day moving average price of $1.05. The firm has a market capitalization of $61.79 million, a PE ratio of -3.14 and a beta of 0.78.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its position in Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after acquiring an additional 8,400 shares during the period. Northern Trust Corp grew its position in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after acquiring an additional 16,701 shares during the period. Skylands Capital LLC grew its position in Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock worth $2,531,000 after acquiring an additional 26,195 shares during the period. Geode Capital Management LLC grew its position in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after acquiring an additional 32,415 shares during the period. Finally, Millennium Management LLC purchased a new position in Cytosorbents in the fourth quarter worth approximately $30,000. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads